WASHINGTON — Pursuant Executive Order 14297, titled Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, the Office of the United States Trade Representative invites comments from interested parties regarding any act, policy, or practice that may be unreasonable or discriminatory and that has the effect of forcing American patients to pay for a disproportionate amount of global pharmaceutical research and development, including by suppressing the price of pharmaceutical products below fair market value in foreign countries.
To be assured of consideration, please submit comments by June 27, 2025.
To view the Federal Register Notice, click here.
Comments in response to this notice can be submitted or accessed here.
###
